It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Explore effective strategies for locating undervalued stocks today. Discover opportunities to maximize your investment gains.
18,306 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
The first half of 2026 handed investors a harsh lesson on how fast sentiment can turn in ad tech. This article breaks...
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Investors are weighing a bold claim: prediction: will lose value for XRP. This article breaks down what could drive X...
Costco stock has flashed sell-side headlines and uncertain momentum. This guide breaks down what a dip means for COST...
A billionaire places a bold personal bet on a private space company. This article breaks down what that move means fo...
IBM’s dramatic one-day plunge coincided with blockbuster bank profits, fueling a debate over whether markets are misp...
When a high-ranking executive at a major company sells shares, it can spark questions about the stock’s outlook. This...
Citadel Advisors remains overweight in Microsoft, neutral on Amazon, and cautious on Apple as AI investment cycles di...
AST SpaceMobile has fallen from its highs even after a sizable funding round. This article explains why the fade in s...
In the first half of 2026, ASML delivered a standout rally as AI-driven demand lifted the semiconductor supply chain....
A bold stake move in Hut 8 has sparked a new conversation about concentration, risk, and opportunity in crypto-relate...